Psoriatic Arthritis - Cimzia reg; Certolizumab Pegol Shows Promise
On Thursday, UCB announced its intention to submit regulatory applications for Cimzia ® (certolizumab pegol) by the end of this year. The drug is designed to treat psoriatic arthritis, an inflammation of the joints, or arthritis, which typically occurs in combination with psoriasis, a skin disorder. People with PsA generally suffer from stiff, painful joints, and experience warmth and swelling in their joints and surrounding tissues. The majority of PsA sufferers develop psoriasis, a common disorder affecting about 2 to 3% of people worldwide, before joint problems occur, however, in some cases the development process can be the other way around.
Growing Up On A Farm Directly Affects Regulation Of The Immune System
Immunological diseases, such as eczema and asthma, are on the increase in westernised society and represent a major challenge for 21st century medicine. A new study has shown, for the first time, that growing up on a farm directly affects the regulation of the immune system and causes a reduction in the immunological responses to food proteins. The research, led by the University of Bristol's School of Veterinary Sciences, found that spending early life in a complex farm environment increased the number of regulatory T-lymphocytes, the cells that damp down the immune system and limit immune responses.
Inhibitor Causing Male Pattern Baldness Discovered
A study published in Science Translational Medicine, from the University of Pennsylvania, explains that scientists looking for the holy grail in beauty treatment have discovered an abnormal quantity of a protein, called Prostaglandin D2, present in the scalp of bald men, that they think may be responsible for their hair loss. Their work should lead directly to the creation of new treatments for the most common cause of hair loss in men, known as male pattern baldness. The problem of male pattern baldness is seen to varying degrees in 8 of 10 men under 70 years old.